阿托伐他汀对急性冠脉综合征患者血清妊娠相关蛋白-A及C反应蛋白的影响

Effects of Atorvastatin on Serum Concentration of PAPP-A and C-Reactive Protein in Patients with Acute Coronary Syndrome

目的:探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清妊娠相关蛋白-A(PAPP-A)和C反应蛋白(CRP)的影响。方法:选取ACS患者(ACS组)105例和正常对照组90例,测定其PAPP-A及CRP水平,将105例ACS患者随机分阿托伐他汀20mg组(高剂量组,51例)和阿托伐他汀10mg组(低剂量组,54例),分别采用20mg和10mg阿托伐他汀治疗1周后,再次测定PAPP-A及CRP水平。结果:ACS组血清PAPP-A和CRP水平高于对照组,差异有统计学意义(P<0.01)。治疗前,高剂量组和低剂量组的PAPP-A及CRP水平差异无统计学意义,治疗后高剂量组和低剂量组的PAPP-A及CRP水平均低于治疗前,治疗后高剂量组的PAPP-A及CRP水平均低于低剂量组,差异均有统计学意义(P<0.01)。结论:阿托伐他汀可以减轻ACS患者的炎症反应,稳定冠脉粥样硬化斑块。

Objective： To investigate effects of atorvastatin on the serum concentration of pregnancy-associated plasma protein （PAPP）-A and C-reactive protein （CRP） in patients with acute coronary syndrome （ACS）. Methods： The serum concentrations of PAPP-A and CRP were measured before and after one week treatment with atorvastatin （20 mg and 10 mg） in 105 ACS patients and 90 control subjects. Results： There were significantly higher serum levels of PAPP-A and CRP in patients with ACS than those of control subjects （P 〈 0.01）. There were no significant differences in serum levels of PAPP-A and CRP before treatment with atorvastatin between 10 mg group and 20 mg group. After treatment with atorvastatin there were lower serum levels in PAPP-A and CRP in these two groups. The serum levels of PAPP-A and CRP were significantly lower in patients with 20 mg atorvastatin treatment than those of patients with 10 mg treatment （P 〈 0.01）. Conclusion： Atorvastatin？can reduce the？inflammation？in patients with ACS,？and stable？coronary atherosclerotic plaque.